CN104342145A - Method for preparing upconversion fluorescent micron particles serving as photodynamic drug carrier - Google Patents
Method for preparing upconversion fluorescent micron particles serving as photodynamic drug carrier Download PDFInfo
- Publication number
- CN104342145A CN104342145A CN201410558235.2A CN201410558235A CN104342145A CN 104342145 A CN104342145 A CN 104342145A CN 201410558235 A CN201410558235 A CN 201410558235A CN 104342145 A CN104342145 A CN 104342145A
- Authority
- CN
- China
- Prior art keywords
- micron particle
- conversion fluorescence
- ybpo
- drug carrier
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 title claims abstract description 71
- 239000003937 drug carrier Substances 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title abstract description 9
- 239000003504 photosensitizing agent Substances 0.000 claims abstract description 41
- 238000005245 sintering Methods 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims description 60
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 18
- 230000003287 optical effect Effects 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 15
- YBYGDBANBWOYIF-UHFFFAOYSA-N erbium(3+);trinitrate Chemical compound [Er+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O YBYGDBANBWOYIF-UHFFFAOYSA-N 0.000 claims description 7
- KUBYTSCYMRPPAG-UHFFFAOYSA-N ytterbium(3+);trinitrate Chemical compound [Yb+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O KUBYTSCYMRPPAG-UHFFFAOYSA-N 0.000 claims description 7
- 230000031700 light absorption Effects 0.000 claims description 6
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 claims description 5
- -1 ions ytterbium orthophosphate Chemical class 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 238000002428 photodynamic therapy Methods 0.000 abstract description 12
- 206010028980 Neoplasm Diseases 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 11
- 238000006552 photochemical reaction Methods 0.000 abstract description 8
- 201000011510 cancer Diseases 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 239000002131 composite material Substances 0.000 abstract description 2
- OSQUFVVXNRMSHL-LTHRDKTGSA-M sodium;3-[(2z)-2-[(e)-4-(1,3-dibutyl-4,6-dioxo-2-sulfanylidene-1,3-diazinan-5-ylidene)but-2-enylidene]-1,3-benzoxazol-3-yl]propane-1-sulfonate Chemical compound [Na+].O=C1N(CCCC)C(=S)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 OSQUFVVXNRMSHL-LTHRDKTGSA-M 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 2
- YXNVQKRHARCEKL-UHFFFAOYSA-K ytterbium(3+);phosphate Chemical compound [Yb+3].[O-]P([O-])([O-])=O YXNVQKRHARCEKL-UHFFFAOYSA-K 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 32
- 210000001519 tissue Anatomy 0.000 description 10
- 239000011246 composite particle Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 8
- 201000007270 liver cancer Diseases 0.000 description 8
- 208000014018 liver neoplasm Diseases 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000009977 dual effect Effects 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229910052691 Erbium Inorganic materials 0.000 description 4
- 229910052769 Ytterbium Inorganic materials 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 3
- 239000012930 cell culture fluid Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000023983 oral cavity neoplasm Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 231100000489 sensitizer Toxicity 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000009871 tenuigenin Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a method for preparing erbium-doped ytterbium phosphate (YbPO4: Er) micron particles which can serve as a photodynamic drug carrier and have an upconversion fluorescence property. According to the method, YbPO4: Er upconversion fluorescent micron particles are prepared firstly by adopting a solvothermal and high-temperature sintering method, and then, are enabled to load a photodynamic therapy drug photosensitizer merocyanine 540 (MC540), thereby obtaining YbPO4: Er-MC540 composite micron particles with a photodynamic curative effect. Compared with other upconversion materials for loading photodynamic drugs, the micron particles have the advantages that the micron particles have luminescent wavelength, which is better matched with the maximum absorption wavelength of the photosensitizer, and can more effectively activate the photochemical reaction of the photosensitizer MC540 under the irradiation of near-infrared light; the material is small in particle size and good in biocompatibility, can be swallowed by cancer cells and can directly transport the photosensitizer into the cells, so that the cancer cells can be more effectively killed.
Description
Technical field
The present invention relates to a kind of synthetic method that can be used as the up-conversion fluorescence micron particle of optical dynamic drug carrier, belong to micro Nano material preparation and the Application Areas in biomedicine thereof.
Background technology
Photodynamic therapy (photo dynamic therapy, PDT) be a kind of cancer treatment method of Noninvasive, need by there is the light of specific wavelength and being called as photosensitizers (photosensitizers, PS) phototherapy medicament, its mechanism of action is based on the photochemical reaction occurred between photosensitizers and ambient oxygen.Photosensitizers is that a class itself stablizes nontoxicity, but can generate the organic molecule of virose singlet oxygen and free radical under specific wavelength light beam irradiates.In photodynamic therapy, photosensitizers is injected body in advance, due to tumor tissues high-selenium corn, low metabolism, after for some time, meeting specific deposition is at tumor tissues.Activate photosensitizers with the rayed of specific wavelength again, produce singlet oxygen and free radical etc. and kill tumour cell, reach therapeutic purpose.
As the treatment means that a kind of invasive is minimum, photodynamic therapy has caused people at biological technical field and has studied interest greatly.But, at present there is a general problem for clinical photodynamic therapy, namely most of photosensitizers only absorbing wavelength can be positioned at the visible ray of 400-700nm wave band, therefore its photochemical reaction can only be activated by visible ray, to implement photodynamic therapy, the biological tissue of photosensitizers must be had with radiation of visible light injection.And biological tissue is very strong to the absorption of visible ray, cause the penetration depth of visible ray in biological tissue very little, only there is several millimeter, organization internal cannot be arrived, the epidermis of tissue can only be acted on, as shallow pathological tissues of table such as skin, esophagus, oral mucosa, lung cancer, wing fleshes, thus its clinical application is limited by very large, and only can be used for the treatment of Superficial Malignant Tumours, the esophageal carcinoma, gastroenteric tumor, mouth neoplasm, bladder cancer etc.If can at the very strong near infrared (near-infrared of tissue penetration, photodynamic therapy is implemented under the irradiation of NIR) light, just can break through these limitations, reason is that biological tissue does not almost absorb near infrared light, compared with visible ray, the tissue penetration depths of near infrared light is larger, and less to biological tissue's injury of health.But, because most of photosensitizers can only absorb visible ray, near infrared light can not be absorbed, therefore, it is possible to the upconverting fluorescent material launching high strength visible ray under near infrared light is placed high hopes by people, they can as photoconverter, first absorbed near infrared light is converted into visible ray, then activated the photochemical reaction of photosensitizers by visible ray, thus solve traditional PD T institute problems faced, for the photodynamic therapy of deep tumor provides possibility.
2007, the people such as Zhang took the lead in reporting the mechanism utilizing up-conversion fluorescence nanoparticle to apply in cancer photodynamic therapy.First they prepared the coated NaYF of thin layer of silicon dioxide
4: Yb, Er (NaYF
4: Yb, Er@SiO
2) up-conversion fluorescence nanoparticle, the near infrared light that this nano material can be 974nm at wavelength issues out the up-conversion fluorescence that wavelength is 537nm and 635nm, the photosensitizers MC540 that wherein fluorescence of 537nm can be 540nm by maximum light absorption wavelength is just absorbed, and activate the photochemical reaction of MC540, use NaYF further
4: Yb, Er load photosensitizers MC540, obtained NaYF
4: Yb, Er@SiO
2-MC540 composite nanoparticle has obvious light power curative effect (J.Am.Chem.Soc., 2007,129,4526-4527) to cancer cells.Since then, researchers are just devoted to the upconverting fluorescent material of development of new always, and it can be used as optical dynamic drug carrier, the various photosensitizers of load.
But the upconverting fluorescent material kind that at present, can be used as optical dynamic drug carrier is still little.Its major cause: one is that the emission wavelength of up-conversion does not mate with the absorbing wavelength of photosensitizers, effectively cannot activate the photochemical reaction of photosensitizers; Two is that the particle size of upconverting fluorescent material is comparatively large, by cytophagy, therefore the photosensitizers of institute's load can not cannot be transported in cell.
Summary of the invention
The present invention is directed to the problem that the upconverting fluorescent material kind that can be used as optical dynamic drug carrier is less, provide a kind of preparation method of novel upconverting fluorescent material, prepared Er ions ytterbium orthophosphate (YbPO by the method
4: Er) up-conversion fluorescence micron particle, this material can load photosensitizers M-540, and green fluorescence can be sent under the irradiation of near infrared light, the maximum light absorption wavelength of its emission wavelength and photosensitizers M-540 closely, effectively can activate the photochemical reaction of M-540.This material particle size is little, good biocompatibility, can be engulfed by cancer cells, the photosensitizers of institute's load directly can be transported in cell, further increase the result for the treatment of of photodynamic therapy.
For achieving the above object, the present invention is achieved through the following technical solutions:
The preparation process of up-conversion fluorescence micron particle of the present invention:
By ytterbium nitrate Yb (NO
3)
3, Erbium trinitrate Er (NO
3)
3, Secondary ammonium phosphate (NH
4)
2hPO
4be dissolved in solvent, be transferred to solvent thermal reaction in autoclave and, after 12 hours, carry out high temperature sintering and prepare Er ions ytterbium orthophosphate (YbPO
4: Er) up-conversion fluorescence micron particle.
Described ytterbium nitrate Yb (NO
3)
3with Erbium trinitrate Er (NO
3)
3the ratio of amount be 100:1 ~ 100:5, be preferably 100:2.5; Ytterbium nitrate Yb (NO
3)
3with Erbium trinitrate Er (NO
3)
3mole number sum and Secondary ammonium phosphate (NH
4)
2hPO
4the ratio of mole number be 1:1.
Described solvent is the mixed solvent of ethylene glycol and glycerol, and the volume ratio of ethylene glycol and glycerol is 1:5 ~ 5:1, is preferably 3:1.
Described solvent thermal reaction temperature is 100 ~ 200 DEG C, is preferably 180 DEG C.
Described high temperature sintering temperature is 800 ~ 1200 DEG C, is preferably 1200 DEG C.
YbPO prepared by aforesaid method
4: Er micron particle is spheroidal particle, and size is about 1 micron, can load photo-dynamical medicine photosensitizers M-540 (MC540).Described YbPO
4: Er micron particle, under the exciting of 980nm near-infrared laser, can launch the up-conversion fluorescence that main peak is positioned at 550nm, and its emission wavelength mates with the maximum light absorption wavelength 540nm of photosensitizers M-540 very much, and mismatch is only 10nm.
Described YbPO
4: the method that Er up-conversion fluorescence micron particle is used as optical dynamic drug carrier is as follows:
Take a certain amount of YbPO
4: Er up-conversion fluorescence micron particle and appropriate photo-dynamical medicine MC540, add appropriate ultrapure water, stirs after 24 hours under normal temperature condition, and product is centrifugal, washing, vacuum-drying, obtain the YbPO that load has photo-dynamical medicine MC540
4: Er-MC540 compound micron particle.
As shown from the above technical solution, the present invention is with ytterbium nitrate, Erbium trinitrate, Secondary ammonium phosphate for main raw material, and ethylene glycol and glycerol are solvent, adopts solvent thermal high-temperature sintering process has prepared the YbPO that can launch up-conversion fluorescence
4: Er micron particle, this micron particle can activate and load photosensitizers MC540, makes the YbPO with light power curative effect
4: Er-MC540 compound micron particle.
Compared with prior art, the invention has the advantages that:
(1) YbPO
4: the main glow peak of Er up-conversion fluorescence micron particle is positioned at 550nm, with the maximum light absorption wavelength 540nm of photosensitizers MC540 closely, mismatch is only 10nm, overcome other up-conversion emission wavelength and the unmatched shortcoming of sensitiser absorption wavelength, thus effectively can activate the photochemical reaction of photosensitizers MC540.
(2) YbPO
4: the particle diameter of Er up-conversion fluorescence micron particle is little, good biocompatibility, can by cytophagy, overcome other changes solid support material can not by cytophagy, the shortcoming that the photosensitizers of institute's load cannot be transported to cell interior.
(3) YbPO disclosed in this invention
4: Er up-conversion fluorescence micron particle can be used for load photosensitizers MC540, in the light power diagnosis and treatment field of deep tumor, have good application prospect.
Accompanying drawing explanation
Fig. 1: YbPO
4: the x-ray diffractogram of powder spectrum of Er up-conversion fluorescence micron particle.
Fig. 2: YbPO
4: the electron scanning micrograph of Er up-conversion fluorescence micron particle.
Fig. 3: YbPO
4: the fluorescence spectrum figure (excitation wavelength lambda of Er up-conversion fluorescence micron particle
eX=980nm).
Fig. 4: (a) photosensitizers M-540 (MC540) aqueous solution; (b) YbPO
4: the aqueous dispersions of Er-MC540 composite particles; (c) YbPO
4: the uv-visible absorption spectra figure of the aqueous dispersions of Er up-conversion fluorescence micron particle.
Fig. 5: YbPO
4: the aqueous dispersions of Er up-conversion fluorescence micron particle, photosensitizers M-540 (MC540) aqueous solution, YbPO
4: the aqueous dispersions of Er-MC540 composite particles.
Fig. 6: the YbPO of different concns
4: Er up-conversion fluorescence micron particle and human liver cancer cell (HepG2 cell) Dual culture be after 24 hours, the relative proliferation rate histogram of cell.
Fig. 7: YbPO
4: Er up-conversion fluorescence micron particle and human liver cancer cell (HepG2 cell) Dual culture be after 12 hours, the laser confocal microscope photo of cell.
Fig. 8: the YbPO of different concns
4: Er-MC540 composite particles is to the histogram of the illumination toxicity of human liver cancer cell (HepG2 cell) and dark toxicity.
Embodiment
Embodiment 1
1, YbPO
4: the preparation of Er up-conversion fluorescence micron particle
Step:
(1) 0.0718g Yb (NO is taken
3)
3, 0.0017g Er (NO
3)
3, 0.0542g (NH
4)
2hPO
4, add 30mL ethylene glycol and 10mL glycerol, at normal temperatures abundant stirring and dissolving;
(2) above-mentioned lysate is transferred in 50mL reactor, solvent thermal reaction 12h at 180 DEG C.
(3) after question response terminates solution cooling, take out sample and carry out centrifugal, after centrifugation washing, carry out 1200 DEG C of high temperature sinterings.
Result:
From the powder x-ray diffraction spectrogram of accompanying drawing 1 product, the product prepared is the YbPO that purity is very high
4, Er element is lower due to doping content, cannot by powder x-ray diffraction spectrogram obtaining information.From the electron scanning micrograph of accompanying drawing 2 product, the YbPO prepared
4: Er is the spheroidal particle of micron level, and size is about 1 μm.From the fluorescence spectrum figure of accompanying drawing 3 product, under the exciting of 980nm near-infrared laser, the YbPO prepared
4: Er micron particle can launch the up-conversion fluorescence of high strength, and its main glow peak is positioned near 550nm, and the maximum light absorption wavelength 540nm of the photosensitizers MC540 shown with accompanying drawing 4 curve a is closely.Good fluorescence property also illustrates that Er element has successfully been doped into YbPO
4lattice in.
2, YbPO
4: Er up-conversion fluorescence micron particle load photosensitizers MC540
Step:
(1) YbPO prepared in appropriate embodiment 1 is taken
4: Er up-conversion fluorescence micron particle, is scattered in ultrapure water, is made into the aqueous dispersions that concentration is 200 μ g/mL; Taking appropriate photosensitizers MC540 is dissolved in ultrapure water, obtains the aqueous solution that concentration is the photosensitizers MC540 of 20 μm.
(2) by above-mentioned YbPO
4: the aqueous solution of Er aqueous dispersions and photosensitizers MC540 mixes under normal temperature condition, stir after 24 hours, product is centrifugal, to remove the photosensitizers MC540 of non-load, again centrifugation is scattered in ultrapure water again, obtains the YbPO that load has photo-dynamical medicine MC540
4: the aqueous dispersions of Er-MC540 composite particles.
Result:
Be red-purple from the aqueous solution of accompanying drawing 5, MC540, YbPO
4: the aqueous dispersions of Er up-conversion fluorescence micron particle, close to colourless solution, obviously becomes red-purple with after MC540 compound, and as can be seen from the curve b of accompanying drawing 4, YbPO
4: the uv-visible absorption spectra of Er-MC540 composite particles has the absorption peak significantly belonging to MC540, and this absorption peak is at the YbPO of non-load MC540
4: not there is (see accompanying drawing 4 curve c) in the uv-visible absorption spectra of Er up-conversion fluorescence micron particle, YbPO is described
4: Er micron particle can useful load photosensitizers MC540.
3, mtt assay evaluates YbPO
4: Er up-conversion fluorescence micron particle cytotoxicity experiment
Step:
(1) human liver cancer cell is inoculated in 96 well culture plates with the density in 4000-6000/hole, in cell culture incubator, cultivates 24 hours (5%CO
2, 37 DEG C).
(2) YbPO prepared in appropriate embodiment 1 is taken
4: Er up-conversion fluorescence micron particle, is scattered in appropriate cell culture fluid, makes YbPO
4: Er mass concentration is 125 ~ 1000 μ g/mL.
(3) YbPO of above-mentioned different concns is got
4: each 100 μ L of Er, inject 96 well culture plates, each concentration 6 hole, with human liver cancer cell Dual culture 12 hours (5%CO
2, 37 DEG C).
(4) YbPO in 96 well culture plates is absorbed
4: Er up-conversion fluorescence micron particle, every hole adds 20 μ L tetramethyl-s azo Zo salt (MTT), continues cultivation 4 hours (5%CO
2, 37 DEG C).
(5) stop cultivating, every hole adds 150 μ L dimethyl sulfoxide (DMSO), 37 DEG C of isothermal vibration 10min, measures the optical density(OD) OD value of each hole at 490nm by microplate reader.
(6) with not with YbPO
4: the cell of Er Dual culture is control group, measures the optical density(OD) OD value of each hole of this group at 490nm by microplate reader.
(7) the relative proliferation rate of cell is calculated as follows:
Result:
From accompanying drawing 6, YbPO
4even if: Er micron particle is under the high density of 1000 μ g/mL, and the relative proliferation rate of cell, namely cell survival rate still reaches more than 95%, the YbPO obtained by explanation
4: Er micron particle has very low cytotoxicity, and biocompatibility is fine.
4, cytophagy experiment
Step:
Take YbPO prepared in 1mg embodiment 1
4: Er up-conversion fluorescence micron particle, is scattered in 5mL cell culture fluid, with human liver cancer cell Dual culture after 12 hours, absorbs nutrient solution, cleans cell 3 times, to remove not by the YbPO engulfed with PBS
4: Er micron particle, then with laser confocal microscope, cell is observed.
Result:
From accompanying drawing 7, YbPO
4: Er up-conversion fluorescence micron particle can engulf by human liver cancer cell, the particle engulfed is arranged in the tenuigenin of cell mostly.Cytophagy YbPO
4: still can keep the good form such as the spindle bodily form, trilateral after Er micron particle, and the spherical morphology of not de-wall dying cell, illustrate that the existing state of cell is good, still can stretch out pseudopodium and be attached to culture plate surface growth, this shows prepared YbPO further
4: Er up-conversion fluorescence micron particle has good biocompatibility.
5, optical dynamic therapy experiment
Step:
(1) YbPO prepared by appropriate embodiment 3 is got
4: Er-MC540 composite particles, is scattered in cell culture fluid, wherein contained YbPO
4: the mass concentration of Er is 125 ~ 1000 μ g/mL.
(2) by the YbPO of above-mentioned different concns
4: Er-MC540 composite particles and human liver cancer cell co-cultivation 12 hours, then by cell at 980nm laser (power density 0.5W/cm
2) under irradiation 3 minutes.In order to avoid the overheating effect that 980nm laser Long-Duration Exposure may cause, when laser radiation is after 1 minute, interval continues to irradiate for 1 minute again, and total irradiation time is 3 minutes.
(3) adopt mtt assay to record the relative proliferation rate of cell, and proliferation rate relative to the cell of non-light group compare.
Result:
As can be seen from accompanying drawing 8, along with YbPO
4: the increase of Er-MC540 composite particles mass concentration, cell is on a declining curve relative to proliferation rate.And, at each YbPO
4: under Er-MC540 mass concentration, the relative proliferation rate of cell of the experimental group (No. 1 group in Fig. 8) after illumination is all decreased significantly compared to non-light group (No. 2 groups in Fig. 8), and this absolutely proves YbPO
4: Er-MC540 composite particles has significant light power curative effect.
Embodiment 2
YbPO
4: the preparation of Er up-conversion fluorescence micron particle
Step:
(1) 0.0718g Yb (NO is taken
3)
3, 0.0035g Er (NO
3)
3, 0.0277g (NH
4)
2hPO
4, add 20mL ethylene glycol and 20mL glycerol, at normal temperatures abundant stirring and dissolving;
(2) above-mentioned lysate is transferred in 50mL reactor, solvent thermal reaction 12h at 150 DEG C.
(3) after question response terminates solution cooling, take out sample and carry out centrifugal, after centrifugation washing, carry out 800 DEG C of high temperature sinterings.
Embodiment 3
YbPO
4: the preparation of Er up-conversion fluorescence micron particle
Step:
(1) 0.1077g Yb (NO is taken
3)
3, 0.0021g Er (NO
3)
3, 0.0404g (NH
4)
2hPO
4, add 10mL ethylene glycol and 30mL glycerol, at normal temperatures abundant stirring and dissolving;
(2) above-mentioned lysate being transferred to volume is in the reactor of 50mL, solvent thermal reaction 12h at 200 DEG C.
(3) after question response terminates solution cooling, take out sample and carry out centrifugal, after centrifugation washing, carry out 1100 DEG C of high temperature sinterings.
Embodiment 4
YbPO
4: the preparation of Er up-conversion fluorescence micron particle
Step:
(1) 0.1436g Yb (NO is taken
3)
3, 0.0035g Er (NO
3)
3, 0.0541g (NH
4)
2hPO
4, add 25mL ethylene glycol and 15mL glycerol, at normal temperatures abundant stirring and dissolving;
(2) above-mentioned lysate being transferred to volume is in the reactor of 50mL, solvent thermal reaction 12h at 180 DEG C.
(3) after question response terminates solution cooling, take out sample and carry out centrifugal, after centrifugation washing, carry out 1200 DEG C of high temperature sinterings.
Embodiment 5
YbPO
4: the preparation of Er up-conversion fluorescence micron particle
Step:
(1) 0.0359g Yb (NO is taken
3)
3, 0.0014g Er (NO
3)
3, 0.0137g (NH
4)
2hPO
4, add 15mL ethylene glycol and 25mL glycerol, at normal temperatures abundant stirring and dissolving;
(2) above-mentioned lysate being transferred to volume is in the reactor of 50mL, solvent thermal reaction 12h at 120 DEG C.
(3) after question response terminates solution cooling, take out sample and carry out centrifugal, after centrifugation washing, carry out 900 DEG C of high temperature sinterings.
Claims (8)
1. be used as a preparation method for the up-conversion fluorescence micron particle of optical dynamic drug carrier, it is characterized in that, the preparation process of described up-conversion fluorescence micron particle is as follows:
By ytterbium nitrate Yb (NO
3)
3, Erbium trinitrate Er (NO
3)
3, Secondary ammonium phosphate (NH
4)
2hPO
4be dissolved in solvent, be transferred to solvent thermal reaction in autoclave and, after 12 hours, through high temperature sintering, prepare Er ions ytterbium orthophosphate (YbPO
4: Er) up-conversion fluorescence micron particle.
2. the preparation method being used as the up-conversion fluorescence micron particle of optical dynamic drug carrier according to claim 1, is characterized in that, ytterbium nitrate Yb (NO
3)
3with Erbium trinitrate Er (NO
3)
3mol ratio be 100:1 ~ 100:5; Ytterbium nitrate Yb (NO
3)
3with Erbium trinitrate Er (NO
3)
3mole number sum and Secondary ammonium phosphate (NH
4)
2hPO
4the ratio of mole number be 1:1.
3. the preparation method being used as the up-conversion fluorescence micron particle of optical dynamic drug carrier according to claim 1, it is characterized in that, described solvent is the mixed solvent of ethylene glycol and glycerol, and the volume ratio of ethylene glycol and glycerol is 1:5 ~ 5:1.
4. the preparation method being used as the up-conversion fluorescence micron particle of optical dynamic drug carrier according to claim 1, it is characterized in that, described solvent thermal reaction temperature is 100 ~ 200 DEG C.
5. the preparation method being used as the up-conversion fluorescence micron particle of optical dynamic drug carrier according to claim 1, it is characterized in that, described high temperature sintering temperature is 800 ~ 1200 DEG C.
6. the preparation method being used as the up-conversion fluorescence micron particle of optical dynamic drug carrier according to claim 1, is characterized in that, described YbPO
4: Er micron particle is spheroidal particle, and size is about 1 micron.
7. the preparation method being used as the up-conversion fluorescence micron particle of optical dynamic drug carrier according to claim 1, is characterized in that, described YbPO
4: Er micron particle can load photo-dynamical medicine photosensitizers M-540 (MC540).
8. the preparation method being used as the up-conversion fluorescence micron particle of optical dynamic drug carrier according to claim 1, is characterized in that, described YbPO
4: Er micron particle, under the exciting of 980nm near-infrared laser, can launch the up-conversion fluorescence that main peak is positioned at 550nm, and its emission wavelength mates with the maximum light absorption wavelength 540nm of photosensitizers M-540 very much, and mismatch is only 10nm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410558235.2A CN104342145B (en) | 2014-10-18 | 2014-10-18 | A kind of preparation method of the up-conversion fluorescence micron particle as optical dynamic drug carrier |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410558235.2A CN104342145B (en) | 2014-10-18 | 2014-10-18 | A kind of preparation method of the up-conversion fluorescence micron particle as optical dynamic drug carrier |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104342145A true CN104342145A (en) | 2015-02-11 |
| CN104342145B CN104342145B (en) | 2016-08-24 |
Family
ID=52498618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410558235.2A Active CN104342145B (en) | 2014-10-18 | 2014-10-18 | A kind of preparation method of the up-conversion fluorescence micron particle as optical dynamic drug carrier |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104342145B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105617379A (en) * | 2016-01-12 | 2016-06-01 | 上海交通大学 | ROS (reactive oxygen species)-response nano drug delivery system as well as preparation method and application thereof |
| CN106753373A (en) * | 2016-11-30 | 2017-05-31 | 青岛科技大学 | A kind of ytterbium thulium codope gadolinium oxide upper conversion fluorescent nano particle and preparation method thereof |
| CN107238592A (en) * | 2017-05-31 | 2017-10-10 | 青岛科技大学 | A kind of ferric ion detection reagent and its preparation method and application |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060039426A1 (en) * | 2004-08-23 | 2006-02-23 | Myers John D | Novel ytterbium-phosphate glass |
| CN101402861A (en) * | 2008-10-29 | 2009-04-08 | 华南理工大学 | Phosphate upconversion luminescent nanocrystalline capable of emitting red light or green light and method of producing the same |
| CN102061163A (en) * | 2010-11-26 | 2011-05-18 | 昆明理工大学 | Method for regulating upconversion emitting color of rare earth illuminant |
| KR20120013156A (en) * | 2010-08-04 | 2012-02-14 | 고려대학교 산학협력단 | solid electrolyte for dye-sensitized solar cells |
| CN102496715A (en) * | 2011-12-22 | 2012-06-13 | 中国计量学院 | Solvothermal method used for preparing LiFePO4 |
-
2014
- 2014-10-18 CN CN201410558235.2A patent/CN104342145B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060039426A1 (en) * | 2004-08-23 | 2006-02-23 | Myers John D | Novel ytterbium-phosphate glass |
| CN101402861A (en) * | 2008-10-29 | 2009-04-08 | 华南理工大学 | Phosphate upconversion luminescent nanocrystalline capable of emitting red light or green light and method of producing the same |
| KR20120013156A (en) * | 2010-08-04 | 2012-02-14 | 고려대학교 산학협력단 | solid electrolyte for dye-sensitized solar cells |
| CN102061163A (en) * | 2010-11-26 | 2011-05-18 | 昆明理工大学 | Method for regulating upconversion emitting color of rare earth illuminant |
| CN102496715A (en) * | 2011-12-22 | 2012-06-13 | 中国计量学院 | Solvothermal method used for preparing LiFePO4 |
Non-Patent Citations (5)
| Title |
|---|
| JIANGCHAO CHEN，ET AL.: "Sensitization of Eu3+ Luminescence in Eu:YPO4 Nanocrystals", 《THE JOURNAL OF PHYSICAL CHEMISTRY C》 * |
| SUNHYUNG LEE，ET AL.: "Fabrication of Upconverting YbPO4:Er Crystals by Naturally-Derived Gel Growth and Subsequent Thermal Treatment", 《CRYSTAL GROWTH & DESIGN》 * |
| ZHANG WENYAN，ET AL.: "Hydrothermal synthesis, structure study and luminescent properties of YbPO4:Tb3+ nanoparticles", 《JOURNAL OF RARE EARTHS》 * |
| 卿冠兰: "溶剂热法制备的稀土掺杂磷酸盐发光性能研究", 《中国优秀硕士学士论文全文数据库-基础科学辑》 * |
| 郭静: "铕掺杂氧化钇和磷酸钇荧光材料的合成与荧光性质研究", 《中国优秀硕士学位论文全文数据库-工程科技Ⅰ辑》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105617379A (en) * | 2016-01-12 | 2016-06-01 | 上海交通大学 | ROS (reactive oxygen species)-response nano drug delivery system as well as preparation method and application thereof |
| CN105617379B (en) * | 2016-01-12 | 2018-12-25 | 上海交通大学 | A kind of Nano medication delivery system and the preparation method and application thereof of ROS response |
| CN106753373A (en) * | 2016-11-30 | 2017-05-31 | 青岛科技大学 | A kind of ytterbium thulium codope gadolinium oxide upper conversion fluorescent nano particle and preparation method thereof |
| CN107238592A (en) * | 2017-05-31 | 2017-10-10 | 青岛科技大学 | A kind of ferric ion detection reagent and its preparation method and application |
| CN107238592B (en) * | 2017-05-31 | 2019-12-06 | 青岛科技大学 | Ferric ion detection reagent and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104342145B (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hamblin | Upconversion in photodynamic therapy: plumbing the depths | |
| Xu et al. | Highly emissive dye-sensitized upconversion nanostructure for dual-photosensitizer photodynamic therapy and bioimaging | |
| JP6824933B2 (en) | Non-invasive energy up-conversion methods and systems for in situ photobiomodulation | |
| Ma et al. | A new X-ray activated nanoparticle photosensitizer for cancer treatment | |
| Zhang et al. | NaYbF 4 nanoparticles as near infrared light excited inorganic photosensitizers for deep penetration in photodynamic therapy | |
| Ruan et al. | Transdermal delivery of multifunctional CaO 2@ Mn-PDA nanoformulations by microneedles for NIR-induced synergistic therapy against skin melanoma | |
| CN108653734B (en) | Efficient up-conversion nanoparticle photosensitizer compound and preparation method and application thereof | |
| CN108815525B (en) | Multifunctional polypyrrole-coated drug-loaded mesoporous titanium dioxide nanoparticle and preparation method thereof | |
| CN112566663B (en) | Triplet-triplet energy transfer excited by long wavelength light and method thereof | |
| Li et al. | Intelligent nanotransducer for deep-tumor hypoxia modulation and enhanced dual-photosensitizer photodynamic therapy | |
| CN111249461A (en) | Preparation and application of phycocyanin-chlorin e6 covalent nanoparticles | |
| Ran et al. | Rhythm Mild‐Temperature Photothermal Therapy Enhancing Immunogenic Cell Death Response in Oral Squamous Cell Carcinoma | |
| CN107137709B (en) | Photodynamic therapy system and method for continuously generating singlet oxygen | |
| CN113559064A (en) | Novel self-oxygen-supply liposome nanoparticle and preparation method and application thereof | |
| Sun et al. | Light conversion nanomaterials for wireless phototherapy | |
| CN104342145B (en) | A kind of preparation method of the up-conversion fluorescence micron particle as optical dynamic drug carrier | |
| Hu et al. | A thermally activated delayed fluorescence photosensitizer for photodynamic therapy of oral squamous cell carcinoma under low laser intensity | |
| Xu et al. | Carbon dots as a promising therapeutic approach for combating cancer | |
| CN106753373A (en) | A kind of ytterbium thulium codope gadolinium oxide upper conversion fluorescent nano particle and preparation method thereof | |
| CN105194679A (en) | Preparation method and application of titanium dioxide-graphene oxide composite material modified by hyaluronic acid of antitumor drug nanometer layer | |
| Xu et al. | PLGA-coated methylene blue nanoparticles for photoacoustic imaging and photodynamic/photothermal cascaded precisely synergistic therapy of tumor | |
| CN107715110B (en) | Biodegradable black phosphorus-based X-ray photodynamic therapy photosensitizer and preparation method and application thereof | |
| Kamarudin et al. | SIRIUS, Ultra-Scintillating Upconversion Breast Implant for Remote Orthotopic Photodynamic Therapy | |
| CN110724517B (en) | Rare earth/chlorophyll composite probe and preparation method and application thereof | |
| CN113230401A (en) | Core-shell up-conversion MOFs photosensitive composite material, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |